Angiogenesis Inhibitors in NSCLC
Class of Agent
•
Monoclonal Antibody
-
Bevacizumab
(anti-VEGF)
-
Ramucirumab (anti-VEGFR2)
•
Small Molecule TKIs
-
NINTEDANIB
, Sorafenib, Sunitinib,
Pazopanib, Vandetanib, Motesanib
Cediranib
•
Vascular Disrupting Agents
-
Vadimezan
•
VEGF-Trap
-
Aflibercept
Clinical Setting
•
1
st
line
-
Bevacizumab
-
Many TKIs
-
Vadimezan
•
Maintenance
-
Sunitinib
-
Pazopanib
•
2
nd
line
-
Many TKIs:
NINTEDANIB
-
Aflibercept
-
Ramucirumab
